Literature DB >> 4016709

Pulmonary metastases in ovarian cancer. Analysis of 357 patients.

V E Kerr, E Cadman.   

Abstract

The pattern of pulmonary involvement from ovarian cancer was evaluated in 357 patients who were seen at the Yale-New Haven Hospital from 1966 to 1975. Thoracic involvement by tumor was found in 169 patients (44.5%), a figure considerably higher than in previous reports. Pleural effusions were present in nearly 75% of patients who had thoracic involvement. Only 73% of the effusions contained identifiable malignant cells. Solid metastases to the pulmonary parenchyma were present in 12.3% of the patients; lymphangitic and nodal spread was observed in only 1% of the patients. The incidence of metastases did not correlate with tumor histologic features. Five-year survival figures were 29% for the control group; 5.6% of the patients who had evidence of thoracic involvement were alive after 5 years compared with a 49% 5-year survival of those patients with no evidence of thoracic involvement. Right-sided lesions produced thoracic metastases more frequently than left-sided lesions. No significant differences with respect to age, race, menopause, smoking history, or autopsy rate were found between those patients with and without pulmonary metastasis. Chest x-ray was found to be of great value in determining pulmonary metastasis; only 6% of patients who were proven by autopsy to have spread of cancer to the thoracic cavity had a chest x-ray that did not show malignancy. The majority of these ten patients had lymphangitic or microvascular disease. No cases of second primary occurring in the lung were noted in this review, although two case reports have appeared in the literature. Only three patients with pulmonary involvement by tumor had no other evidence of Stage IV disease.

Entities:  

Mesh:

Year:  1985        PMID: 4016709     DOI: 10.1002/1097-0142(19850901)56:5<1209::aid-cncr2820560542>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma.

Authors:  Sarah I Kamel; Mechteld C de Jong; Richard D Schulick; Teresa P Diaz-Montes; Christopher L Wolfgang; Kenzo Hirose; Barish H Edil; Michael A Choti; Robert A Anders; Timothy M Pawlik
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

2.  Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group.

Authors:  Elizabeth A Sadowski; Atul B Shinagare; Hyesun Park; Olga R Brook; Rosemarie Forstner; Sumer K Wallace; Jeanne M Horowitz; Neil Horowitz; Marcia Javitt; Priyanka Jha; Aki Kido; Yulia Lakhman; Susanna I Lee; Lucia Manganaro; Katherine E Maturen; Stephanie Nougaret; Liina Poder; Gaiane M Rauch; Caroline Reinhold; Evis Sala; Isabelle Thomassin-Naggara; Herbert Alberto Vargas; Aradhana Venkatesan; Olivera Nikolic; Andrea G Rockall
Journal:  Eur Radiol       Date:  2021-11-30       Impact factor: 7.034

3.  Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.

Authors:  Minati Satpathy; Liya Wang; Rafal Zielinski; Weiping Qian; Malgorzata Lipowska; Jacek Capala; Gee Young Lee; Hong Xu; Y Andrew Wang; Hui Mao; Lily Yang
Journal:  Small       Date:  2013-08-27       Impact factor: 13.281

Review 4.  Evidence-Based Cancer Imaging.

Authors:  Atul B Shinagare; Ramin Khorasani
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

Review 5.  Uncommon Metastasis of Ovarian Dysgerminoma: A Case Report and Review of the Literature.

Authors:  Mihaela Camelia Tîrnovanu; Irina Daniela Florea; Adina Tănase; Bogdan Florin Toma; Elena Cojocaru; Carmen Ungureanu; Ludmila Lozneanu
Journal:  Medicina (Kaunas)       Date:  2021-05-27       Impact factor: 2.430

6.  Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.

Authors:  L Zhang; T Ma; J Brozick; K Babalola; R Budiu; G Tseng; A M Vlad
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

7.  Development and validation of a nomogram to predict synchronous lung metastases in patients with ovarian cancer: a large cohort study.

Authors:  Yufei Yuan; Fanfan Guo; Ruoran Wang; Yidan Zhang; Guiqin Bai
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

8.  Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis.

Authors:  Thanh Truong Giang Ly; Jisoo Yun; Jong-Seong Ha; Yeon-Ju Kim; Woong-Bi Jang; Thi Hong Van Le; Vinoth Kumar Rethineswaran; Jaewoo Choi; Jae-Ho Kim; Sang-Hyun Min; Dong-Hyung Lee; Ju-Seok Yang; Joo-Seop Chung; Sang-Mo Kwon
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

Review 9.  Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.

Authors:  Giulia Scotto; Fulvio Borella; Margherita Turinetto; Valentina Tuninetti; Anna A Valsecchi; Gaia Giannone; Stefano Cosma; Chiara Benedetto; Giorgio Valabrega
Journal:  Cells       Date:  2021-12-03       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.